Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"ADXS < $1"...
After ADXS collapses under $1 because of the coming guaranteed mass dilution & that BP knows AXAL is a dud so no buy out, ADXS will get kicked off the NASDQ because of the $1 share price rule. Then comes the fatal REVERSE SPLIT AGAIN. ADXS shareholders will watch their money disappear right before their unbelieving eyes.
Once again the ADXS POS makes new all time lows. No buy out even though ADXS could be bought today for less than peanuts because BP, especially Amgen, know that AXAL is a dud & will not get FDA or EU approval. Those who gambled their money on ADXS science are tortured daily watching their money disappear right before their eyes. It's ADXS Chinese water torture & death by a thousand ADXS cuts.
"Sell the Company to AMGN, give them the keys, they have the money and the management to get ADXS science to the finish line and save countless lives". That is what should happen. The problem is that Amgen, who knows more about ADXS than any BP, knows that AXAL is a dud & will not get FDA or EU approval. IF AMGN believed AXAL is the real deal, Amgen would have already bought out ADXS for what to Amgen is peanuts. Very small financial risk for a possible monster monetary reward, would be a terrific deal for Amgen, IF Amgen believed AXAL is the real deal, which they don't.
The market once again turned thumbs down on tough Tony Lombardo & his pathetic ADXS conference call. The most perplexing thing about ADXS is why any BP, Amgen in particular, does not buy out ADXS at this very cheap market cap. IF AXAL is the real deal, then ADXS is right now the biggest steal in history for any BP that believes AXAL could get FDA & EU approval based on current trials. The cost to Amgen or any other BP to buy out ADXS is absolute peanuts. Very small financial risk for a possible MONSTER reward. The burning question is, IF AXAL is the real deal why no buy out?
BSTN share price COLLAPSE & REVERSE SPLIT ALERT. The BSTN share price will collapse again to zero bid because the owners of the death spiral floorless convertible debt will continue to convert causing more enormous mass dilution that will collapse the share price AGAIN. That will be followed by ANOTHER monster reverse split. Current BSTN shareholders will see ALL the money they gambled on BSTN stock evaporate right before their disbelieving eyes
The 4 analysts offering 12-month price forecasts for Advaxis Inc have a median target of 21.50, with a high estimate of 24.00 and a low estimate of 19.00. The median estimate represents a +988.61% increase from the last price of 1.98. If the companies these analyst work for would put their money where their mouths are & bought heavily, they could easily force the sitting ducks shorts to cover, explode the ADXS share price & change the character of the stock. Since they liked ADXS at median average $21.5 they should be buying big time at $2 assuming they believe their own recommendation. They have to be aware of the big ADXS short position so the question is, why aren't they buying now at $2?
IF ADXS is truly being manipulated, then manipulators could easily make tons of money "manipulating" the stock up from $2. Buying by manipulators could easily force the shorts to cover & quickly explode the stock & the warrants. The shorts are like sitting ducks to any manipulators who want to make monster money in ADXS. Question is, why aren't the manipulators taking advantage of this golden opportunity?
Both ADXS & ADRO have collaborations with Merck.
Aduro Announces Milestone Achieved under Merck Collaboration for Initiation of Anti-CD27 Phase I Trial in Advanced Solid Tumors BERKELEY, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (ADRO) today announced that the company earned a $3.0 million development milestone payment under its worldwide licensing agreement with Merck (known as MSD outside the United States and Canada) for the initiation of a Phase I clinical trial of its anti-CD27 antibody. The Phase 1 trial is designed to evaluate the safety and pharmacokinetics of the anti-CD27 antibody when administered alone and in combination with pembrolizumab in adults with advanced solid tumors.
“We are pleased with the strong progress Merck has made in the development of our anti-CD27 antibody,” stated Hans van Eenennaam, Ph.D., executive vice president of antibody research and site head, Aduro Biotech Europe. “This marks an important step forward in the advancement of our proprietary B-select monoclonal antibody technology, as the second antibody to enter the clinic.”
Floorless toxic convertible death spiral financing explained. This is why BSTN will eventually again collapse to .0001 & there will be another monster reverse split.......................................Convertible Securities
A "convertible security" is a security—usually a bond or a preferred stock—that can be converted into a different security—typically shares of the company's common stock. In most cases, the holder of the convertible determines whether and when to convert. In other cases, the company has the right to determine when the conversion occurs.
Companies generally issue convertible securities to raise money. Companies that have access to conventional means of raising capital (such as public offerings and bank financings) might offer convertible securities for particular business reasons. Companies that may be unable to tap conventional sources of funding sometimes offer convertible securities as a way to raise money more quickly. In a conventional convertible security financing, the conversion formula is generally fixed - meaning that the convertible security converts into common stock based on a fixed price. The convertible security financing arrangements might also include caps or other provisions to limit dilution (the reduction in earnings per share and proportional ownership that occurs when, for example, holders of convertible securities convert those securities into common stock).
By contrast, in less conventional convertible security financings, the conversion ratio may be based on fluctuating market prices to determine the number of shares of common stock to be issued on conversion. A market price based conversion formula protects the holders of the convertibles against price declines, while subjecting both the company and the holders of its common stock to certain risks. Because a market price based conversion formula can lead to dramatic stock price reductions and corresponding negative effects on both the company and its shareholders, convertible security financings with market price based conversion ratios have colloquially been called "floorless", "toxic," "death spiral," and "ratchet" convertibles.
Both investors and companies should understand that market price based convertible security deals can affect the company and possibly lower the value of its securities. Here's how these deals tend to work and the risks they pose:
* The company issues convertible securities that allow the holders to convert their securities to common stock at a discount to the market price at the time of conversion. That means that the lower the stock price, the more shares the company must issue on conversion.
* The more shares the company issues on conversion, the greater the dilution to the company's shareholders will be. The company will have more shares outstanding after the conversion, revenues per share will be lower, and individual investors will own proportionally less of the company. While dilution can occur with either fixed or market price based conversion formulas, the risk of potential adverse effects increases with a market price based conversion formula.
* The greater the dilution, the greater the potential that the stock price per share will fall. The more the stock price falls, the greater the number of shares the company may have to issue in future conversions and the harder it might be for the company to obtain other financing.
Before you decide to invest in a company, you should find out what types of financings the company has engaged in - including convertible security deals - and make sure that you understand the effects those financings might have on the company and the value of its securities. You can do this by researching the company in the SEC's EDGAR database and looking at the company's registration statements and other filings. Even if the company sells convertible securities in a private, unregistered transaction (or "private placement"), the company and the purchaser normally agree that the company will register the underlying common stock for the purchaser's resale prior to conversion. You'll also find disclosures about these and other financings in the company's annual and quarterly reports on Forms 10-K and 10-Q, respectively, and in any interim reports on Form 8-K that announce the financing transaction.
If the company has engaged in convertible security financings, be sure to ascertain the nature of the convertible financing arrangement - fixed versus market price based conversion ratios. Be sure you fully understand the terms of the convertible security financing arrangement, including the circumstances of its issuance and how the conversion formula works. You should also understand the risks and the possible effects on the company and its outstanding securities arising from the below market price conversions and potentially significant additional share issuances and sales, including dilution to shareholders. You should be aware of the risks arising from the effects of the purchasers and other parties trading strategies, such as short selling activities, on the market price for the company's securities, which may affect the amount of shares issued on future conversions.
Companies should also understand the terms and risks of convertible security arrangements so that they can appropriately evaluate the issues that arise. Companies entering into these types of convertible securities transactions should understand fully the effects that the market price based conversion ratio may have on the company and the market for its securities. Companies should also consider the effect that significant share issuances and below market conversions have on a company's ability to obtain other financing.
Bottom line, there is no buy out because BP, especially Amgen, & the shorts know that AXAL is a dud & will not get FDA & EU approval.
Just goes to show how phony, ignorant & wrong the ADXS analysts are. They sure don't put their money where their mouths are. LOL
ADXS management has shamefully screwed the warrant holders. These warrants were issued five years ago with a $5 strike & expire this OCT. Since the company just massively diluted ADXS shareholders with a $2 funding, extending the expiration of the warrants until AXAL trials are complete would be the give the warrant holders an opportunity to stay in the game & provide ADXS with possible future funding for at least $5 which is a lot better than the $2 funding the incompetent ADXS management just foisted on all ADXS shareholders. However doing the right thing for share & warrant holders has never been a forte of ADXS management so unless there is a buy out before OCT, ADXS management has effectively murdered the warrant holders.
"You are confusing the share price with substance. The share price currently has no connection to the value of the science"...What a crock of nonsense. The share price has EVERYTHING to do with the value of the science. That is why NO BP buy out & why the ADXS share price is trading near ALL TIME LOWS. LOL
"Yep. A track record of good trial results"... Yep. The trial results were so good that the ADXS share price has collapsed 94% from it's high & NOW is trading right around all time lows. Yep, gotta love those good trial results. BP is so impressed with the good trial results that NO BP, especially AMGEN, wants to buy this pig for less than peanuts.
"bargain basement buying opportunity. get it while you can". To bad that no BP believe that ADXS is a "bargain basement opportunity". BP knows better & that is why there is no BP buy out for ADXS which can now be bought for less than peanuts.
IF AXAL is the real deal & will obtain FDA & EU approval, why have NO BP, especially Amgen, not swooped in at this time when they could easily buy out ADXS literally for PEANUTS?
"So you follow ADXS so closely as to know the final outcome of the science,"... It not me that knows the outcome of the science, it's BP, Amgen & the shorts that believe AXAL is a dud & won't get FDA approval. That's why there is no buy out, why the shorts don't cover & why the share price collapsed. Amgen still owning their ADXS shares, displays how insignificant those shares are to Amgen.
Amgen paid about $8.20 a share for ADXS stock. IF Amgen is still holding the stock it shows how little Amgen cares about ADXS as Amgen could buy out ADXS now for peanuts. Kindly provide proof that Amgen still owns it's ADXS stock.
"If it weren't for the gross mismanagement of our company, our share price and market cap wouldn't have collapsed to its current levels." ....What a crock of nonsense. The share price collapsed because BP & the shorts know that AXAL is a dud & will not obtain FDA & EU approval. That is why there has been NO buy out, why the shorts don't cover & why the share has collapsed. Amgen, who knows more about ADXS than any other BP, could & would buy out ADXS for peanuts if Amgen believed AXAL was the real deal.
Bottom line is that zero BP has any interest in buying out ADXS because BP knows AXAL is a dud & will not get FDA or EU approval. Unfortunately those that believe AXAL is the real deal are the ADXS bagholders.
"Dud? More like FUD"....;. AXAL listeria therapy is the dud & the FUD ...Aduro Biotech, Inc. (Nasdaq: ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today provided an update on its clinical development programs for CRS-207, a first-generation proprietary attenuated strain of Listeria that has been engineered to express the tumor-associated antigen mesothelin. Based on preliminary results from its mesothelioma and ovarian studies, as well as a business and commercial assessment, the company has determined that it will not continue advancement of CRS-207 and will wind down each of its trials in mesothelioma, ovarian and gastric cancer. Aduro will be working closely with investigators to proceed in a manner that is aligned with the best interests of patients still being treated on these studies.
The only hope left for ADXS is a buy out which wont happen because BP knows that AXAL is a dud. The most damming evidence of this is that ADRO, a rival & a far more respected company than ADXS also utilized listeria therapy to fight cancer. ADRO has terminated their listeria trials because ADRO's management discovered from the results of their trials that the listeria science is a dud & wouldn't get FDA approval. Therefore ADRO terminated their listeria therapy trials as a cancer cure.
"Cutler Capital Management, LLC increased their position by 26K from 50,000 shares." Cutler bought a stone cold loser & is losing big time already. Very dim bulbs this Cutler Capital Management.
" I will go down with the ship and die a watery death trying to get there"... The name of your ship is THE TITANIC.
"Even if whatever you saying is true, there is no point of selling at this level. $2.65
I rather watch this one die then sell it at this level.".... Make plans for ADXS the funeral.
"ADRO couldn’t afford to buy ADXS."...ADRO wants no part of ADXS because it knows AXAL is a dud. ADRO was wise enough to terminate their listeria trials.
ADXS crashing to NEW 52 week lows because the market, BP, especially AMGEN & ADRO, & the shorts know that AXAL is a dud & will not obtain FDA or EU approval. The dreamers are praying day & night for a buy out to bail out of this ugly piece of garbage stock. ADXS is nothing more than a dream crusher.
"Please, yes, let's all send ADRO flowers so they buy us out"... ADRO will never buy ADXS because ADRO knows AXAL is a dud & will not get FDA or EU approval. ADRO knows a dud when they see one & that it why ADRO wisely TERMINATED their listeria trials.
"I expected we would have seen a deal development on AXAL by now" There is no buy out in spite of the fact that ADXS could be bought out for peanuts, because BP & the shorts know that AXAL is a stone cold dud & will not obtain FDA or EU approval. AMGEN knows more about ADXS than any other BP. AMGEN cherry picked ADXS - NEO because AMGEN believed NEO could be the real deal. If AMGEN believed that AXAL could be the real deal, they could easily buy out ADXS for absolute peanuts clearly illustrating that AMGEN believes AXAL is a dud. In addition ADURO, the only other company developing the listeria cancer science terminated their listeria trials.
BSTN reverse split share price COLLAPSE ALERT. The BSTN share price will collapse again to zero bid because the owners of the death spiral floorless convertible debt will continue to convert causing more enormous mass dilution that will collapse the share price AGAIN. That will be followed by ANOTHER monster reverse split. Current BSTN shareholders will see ALL the money they gambled on BSTN stock evaporate right before their disbelieving eyes.
"That would dilute the company roughly 6-7% if they did that. How would SH's feel about that?"... How are the shareholders going to feel about the mass dilution that will take place when the next funding deal is consummated under the $5 warrant strike price? LOL
The warrants were issued five long years ago. They will probably expire worthless because of the bumbling incompetence of ADXS previous & current management. The warrant holders deserve at least a punchers chance of making money on the warrants. That is what a two year extension would give them & it could be a future source of funding, if a miracle happens & ADXS ever trades above $5 again.
Another example of the stupidity & incompetence of ADXS management. The warrants expire this October. The strike price is $5 with ADXS trading under $3. If ADXS management wasn't such a bunch of donkeys, they would immediately extend the term of the $5 warrants for another 2 years. The warrants would be a possible future source of income assuming ADXS can trade above $5 in the next two years. This would give the warrant holders the chance to allow time to possibly overcome ADXS bumbling, fumbling incompetent management.
Gilead bought out KITE BEFORE it was a sure thing & before FDA approval. ADXS can be bought out today for peanuts but zero BP are are knocking on ADSX's door to buy AXAL which would offer billions in rewards if BP believed AXAL is the real deal which they don't.
"Yet another opinion being presented as fact."...The undeniable fact, not opinion, is there is no buy out of ADXS by any BP because BP knows that AXAL will not get FDA or EU approval. If that were not true & BP believed AXAL was the real deal, then AMGEN & other BP would have bought out ADXS for peanuts because it would give BP the opportunity for a very low monetary risk investment that would return billions in monetary rewards for their shareholders.
" If you had said "there has been not buyout of ADXS" it would be a fact, but you said "buyout attempt".... Ok, there has not been any buy out of ADXS, because AMGEN & other BP know that AXAL is a dud & will not get FDA or EU approval, otherwise ADXS would have been bought out for what is now peanuts. The monetary risk for any BP to buy out ADXS is very low compared to the potential monster monetary rewards if AXAL is the real deal, which it isn't. Bottom line it is risk versus reward for BP to do any buy out. That is why there has been no buy out of ADXS. BP knows the rewards will not materialize.
" Please verify with the company and do let us know what facts they provided you".. What silly logic. The fact, not the opinion, that ZERO BP, especially AMGEN, wants to buy out ADXS is a fact. Facts remain facts and opinions remain opinions.
Facts remain facts and opinions remain opinions."... The only statement that is FACT & not opinion is that ZERO BP has made a buy out attempt of ADXS because they know AXAL is a dud. If this was not fact, ADXS would have been bought out for peanuts by now. Facts remain facts.
"But what does BP know?"... BP knows that AXAL is a dud & will not obtain FDA or EU approval. That's what BP & especially AMGEN knows.
"Facts remain facts, Rmarc. Why deny? Best, Terry"...
ZERO BP including AMGEN, who knows more about ADXS than any other BP, have made any buy out attempts because they know that AXAL is a dud & will not obtain FDA or EU approval. Facts remain facts, Terry, why deny.... Best, rmarc.